Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer

Lichao Sun, Joseph Burnett, Mari Gasparyan, Fangying Xu, Hui Jiang, Chang Ching Lin, Ila Myers, Hasan Korkaya, Yajing Liu, Jamie Connarn, Huining He, Ning Zhang, Max S. Wicha, Duxin Sun

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Continued use of trastuzumab in PTEN-deficient HER2+ breast cancer induces the epithelial-to-mesenchymal transition (EMT), transforms HER2+ to triple negative breast cancer, and expands breast cancer stem cells (BCSCs). Using cancer cell lines with two distinct states, epithelial and mesenchymal, we identified novel targets during EMT in PTEN-deficient trastuzumab-resistant breast cancer. Differential gene expression and distinct responses to a small molecule in BT474 (HER2+ trastuzumabsensitive) and the PTEN-deficient trastuzumab-resistant derivative (BT474-PTEN-LTT) provided the selection tools to identify targets during EMT. siRNA knockdown and small molecule inhibition confirmed MEOX1 as one of the critical molecular targets to regulate both BCSCs and mesenchymal-like cell proliferation. MEOX1 was associated with poor survival, lymph node metastasis, and stage of breast cancer patients. These findings suggest that MEOX1 is a clinically relevant novel target in BCSCs and mesenchymal-like cancer cells in PTEN-deficient trastuzumab resistant breast cancer and may serve as target for future drug development.

Original languageEnglish (US)
Pages (from-to)51408-51422
Number of pages15
JournalOncotarget
Volume7
Issue number32
DOIs
StatePublished - Aug 1 2016

Fingerprint

Epithelial-Mesenchymal Transition
Neoplastic Stem Cells
Breast Neoplasms
Triple Negative Breast Neoplasms
Trastuzumab
Small Interfering RNA
Neoplasms
Lymph Nodes
Cell Proliferation
Neoplasm Metastasis
Gene Expression
Cell Line
Survival

Keywords

  • Cancer stem cells
  • EMT
  • HER2+ breast cancer
  • MEOX1
  • Trastuzumab resistance

ASJC Scopus subject areas

  • Oncology

Cite this

Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer. / Sun, Lichao; Burnett, Joseph; Gasparyan, Mari; Xu, Fangying; Jiang, Hui; Lin, Chang Ching; Myers, Ila; Korkaya, Hasan; Liu, Yajing; Connarn, Jamie; He, Huining; Zhang, Ning; Wicha, Max S.; Sun, Duxin.

In: Oncotarget, Vol. 7, No. 32, 01.08.2016, p. 51408-51422.

Research output: Contribution to journalArticle

Sun, L, Burnett, J, Gasparyan, M, Xu, F, Jiang, H, Lin, CC, Myers, I, Korkaya, H, Liu, Y, Connarn, J, He, H, Zhang, N, Wicha, MS & Sun, D 2016, 'Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer', Oncotarget, vol. 7, no. 32, pp. 51408-51422. https://doi.org/10.18632/oncotarget.9839
Sun, Lichao ; Burnett, Joseph ; Gasparyan, Mari ; Xu, Fangying ; Jiang, Hui ; Lin, Chang Ching ; Myers, Ila ; Korkaya, Hasan ; Liu, Yajing ; Connarn, Jamie ; He, Huining ; Zhang, Ning ; Wicha, Max S. ; Sun, Duxin. / Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer. In: Oncotarget. 2016 ; Vol. 7, No. 32. pp. 51408-51422.
@article{c623d748b1fd4a449469542c2bee14c3,
title = "Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer",
abstract = "Continued use of trastuzumab in PTEN-deficient HER2+ breast cancer induces the epithelial-to-mesenchymal transition (EMT), transforms HER2+ to triple negative breast cancer, and expands breast cancer stem cells (BCSCs). Using cancer cell lines with two distinct states, epithelial and mesenchymal, we identified novel targets during EMT in PTEN-deficient trastuzumab-resistant breast cancer. Differential gene expression and distinct responses to a small molecule in BT474 (HER2+ trastuzumabsensitive) and the PTEN-deficient trastuzumab-resistant derivative (BT474-PTEN-LTT) provided the selection tools to identify targets during EMT. siRNA knockdown and small molecule inhibition confirmed MEOX1 as one of the critical molecular targets to regulate both BCSCs and mesenchymal-like cell proliferation. MEOX1 was associated with poor survival, lymph node metastasis, and stage of breast cancer patients. These findings suggest that MEOX1 is a clinically relevant novel target in BCSCs and mesenchymal-like cancer cells in PTEN-deficient trastuzumab resistant breast cancer and may serve as target for future drug development.",
keywords = "Cancer stem cells, EMT, HER2+ breast cancer, MEOX1, Trastuzumab resistance",
author = "Lichao Sun and Joseph Burnett and Mari Gasparyan and Fangying Xu and Hui Jiang and Lin, {Chang Ching} and Ila Myers and Hasan Korkaya and Yajing Liu and Jamie Connarn and Huining He and Ning Zhang and Wicha, {Max S.} and Duxin Sun",
year = "2016",
month = "8",
day = "1",
doi = "10.18632/oncotarget.9839",
language = "English (US)",
volume = "7",
pages = "51408--51422",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "32",

}

TY - JOUR

T1 - Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer

AU - Sun, Lichao

AU - Burnett, Joseph

AU - Gasparyan, Mari

AU - Xu, Fangying

AU - Jiang, Hui

AU - Lin, Chang Ching

AU - Myers, Ila

AU - Korkaya, Hasan

AU - Liu, Yajing

AU - Connarn, Jamie

AU - He, Huining

AU - Zhang, Ning

AU - Wicha, Max S.

AU - Sun, Duxin

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Continued use of trastuzumab in PTEN-deficient HER2+ breast cancer induces the epithelial-to-mesenchymal transition (EMT), transforms HER2+ to triple negative breast cancer, and expands breast cancer stem cells (BCSCs). Using cancer cell lines with two distinct states, epithelial and mesenchymal, we identified novel targets during EMT in PTEN-deficient trastuzumab-resistant breast cancer. Differential gene expression and distinct responses to a small molecule in BT474 (HER2+ trastuzumabsensitive) and the PTEN-deficient trastuzumab-resistant derivative (BT474-PTEN-LTT) provided the selection tools to identify targets during EMT. siRNA knockdown and small molecule inhibition confirmed MEOX1 as one of the critical molecular targets to regulate both BCSCs and mesenchymal-like cell proliferation. MEOX1 was associated with poor survival, lymph node metastasis, and stage of breast cancer patients. These findings suggest that MEOX1 is a clinically relevant novel target in BCSCs and mesenchymal-like cancer cells in PTEN-deficient trastuzumab resistant breast cancer and may serve as target for future drug development.

AB - Continued use of trastuzumab in PTEN-deficient HER2+ breast cancer induces the epithelial-to-mesenchymal transition (EMT), transforms HER2+ to triple negative breast cancer, and expands breast cancer stem cells (BCSCs). Using cancer cell lines with two distinct states, epithelial and mesenchymal, we identified novel targets during EMT in PTEN-deficient trastuzumab-resistant breast cancer. Differential gene expression and distinct responses to a small molecule in BT474 (HER2+ trastuzumabsensitive) and the PTEN-deficient trastuzumab-resistant derivative (BT474-PTEN-LTT) provided the selection tools to identify targets during EMT. siRNA knockdown and small molecule inhibition confirmed MEOX1 as one of the critical molecular targets to regulate both BCSCs and mesenchymal-like cell proliferation. MEOX1 was associated with poor survival, lymph node metastasis, and stage of breast cancer patients. These findings suggest that MEOX1 is a clinically relevant novel target in BCSCs and mesenchymal-like cancer cells in PTEN-deficient trastuzumab resistant breast cancer and may serve as target for future drug development.

KW - Cancer stem cells

KW - EMT

KW - HER2+ breast cancer

KW - MEOX1

KW - Trastuzumab resistance

UR - http://www.scopus.com/inward/record.url?scp=84982262332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982262332&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9839

DO - 10.18632/oncotarget.9839

M3 - Article

C2 - 27285982

AN - SCOPUS:84982262332

VL - 7

SP - 51408

EP - 51422

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 32

ER -